644 related articles for article (PubMed ID: 29649002)
1. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
Sanchez GAM; Reinhardt A; Ramsey S; Wittkowski H; Hashkes PJ; Berkun Y; Schalm S; Murias S; Dare JA; Brown D; Stone DL; Gao L; Klausmeier T; Foell D; de Jesus AA; Chapelle DC; Kim H; Dill S; Colbert RA; Failla L; Kost B; O'Brien M; Reynolds JC; Folio LR; Calvo KR; Paul SM; Weir N; Brofferio A; Soldatos A; Biancotto A; Cowen EW; Digiovanna JJ; Gadina M; Lipton AJ; Hadigan C; Holland SM; Fontana J; Alawad AS; Brown RJ; Rother KI; Heller T; Brooks KM; Kumar P; Brooks SR; Waldman M; Singh HK; Nickeleit V; Silk M; Prakash A; Janes JM; Ozen S; Wakim PG; Brogan PA; Macias WL; Goldbach-Mansky R
J Clin Invest; 2018 Jul; 128(7):3041-3052. PubMed ID: 29649002
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.
Kim H; Brooks KM; Tang CC; Wakim P; Blake M; Brooks SR; Montealegre Sanchez GA; de Jesus AA; Huang Y; Tsai WL; Gadina M; Prakash A; Janes JM; Zhang X; Macias WL; Kumar P; Goldbach-Mansky R
Clin Pharmacol Ther; 2018 Aug; 104(2):364-373. PubMed ID: 29134648
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).
Kanazawa N; Ishii T; Takita Y; Nishikawa A; Nishikomori R
Pediatr Rheumatol Online J; 2023 Apr; 21(1):38. PubMed ID: 37087470
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW
Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review.
Gómez-Arias PJ; Gómez-García F; Hernández-Parada J; Montilla-López AM; Ruano J; Parra-Peralbo E
Dermatol Ther (Heidelb); 2021 Jun; 11(3):733-750. PubMed ID: 33856640
[TBL] [Abstract][Full Text] [Related]
6. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
Guttman-Yassky E; Silverberg JI; Nemoto O; Forman SB; Wilke A; Prescilla R; de la Peña A; Nunes FP; Janes J; Gamalo M; Donley D; Paik J; DeLozier AM; Nickoloff BJ; Simpson EL
J Am Acad Dermatol; 2019 Apr; 80(4):913-921.e9. PubMed ID: 29410014
[TBL] [Abstract][Full Text] [Related]
7. Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies.
Kim H; Gunter-Rahman F; McGrath JA; Lee E; de Jesus AA; Targoff IN; Huang Y; O'Hanlon TP; Tsai WL; Gadina M; Miller FW; Goldbach-Mansky R; Rider LG
Arthritis Res Ther; 2020 Apr; 22(1):69. PubMed ID: 32252809
[TBL] [Abstract][Full Text] [Related]
8. Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome.
Boyadzhiev M; Marinov L; Boyadzhiev V; Iotova V; Aksentijevich I; Hambleton S
Pediatr Rheumatol Online J; 2019 May; 17(1):19. PubMed ID: 31046790
[TBL] [Abstract][Full Text] [Related]
9. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
10. Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Genovese MC; Kremer J; Zamani O; Ludivico C; Krogulec M; Xie L; Beattie SD; Koch AE; Cardillo TE; Rooney TP; Macias WL; de Bono S; Schlichting DE; Smolen JS
N Engl J Med; 2016 Mar; 374(13):1243-52. PubMed ID: 27028914
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Reich K; Kabashima K; Peris K; Silverberg JI; Eichenfield LF; Bieber T; Kaszuba A; Kolodsick J; Yang FE; Gamalo M; Brinker DR; DeLozier AM; Janes JM; Nunes FP; Thyssen JP; Simpson EL
JAMA Dermatol; 2020 Dec; 156(12):1333-1343. PubMed ID: 33001140
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
13. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Dougados M; van der Heijde D; Chen YC; Greenwald M; Drescher E; Liu J; Beattie S; Witt S; de la Torre I; Gaich C; Rooney T; Schlichting D; de Bono S; Emery P
Ann Rheum Dis; 2017 Jan; 76(1):88-95. PubMed ID: 27689735
[TBL] [Abstract][Full Text] [Related]
14. Development of a Validated Interferon Score Using NanoString Technology.
Kim H; de Jesus AA; Brooks SR; Liu Y; Huang Y; VanTries R; Montealegre Sanchez GA; Rotman Y; Gadina M; Goldbach-Mansky R
J Interferon Cytokine Res; 2018 Apr; 38(4):171-185. PubMed ID: 29638206
[TBL] [Abstract][Full Text] [Related]
15. JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.
Tuttle KR; Brosius FC; Adler SG; Kretzler M; Mehta RL; Tumlin JA; Tanaka Y; Haneda M; Liu J; Silk ME; Cardillo TE; Duffin KL; Haas JV; Macias WL; Nunes FP; Janes JM
Nephrol Dial Transplant; 2018 Nov; 33(11):1950-1959. PubMed ID: 29481660
[TBL] [Abstract][Full Text] [Related]
16. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
Papp KA; Menter MA; Raman M; Disch D; Schlichting DE; Gaich C; Macias W; Zhang X; Janes JM
Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib: A Review in Rheumatoid Arthritis.
Al-Salama ZT; Scott LJ
Drugs; 2018 May; 78(7):761-772. PubMed ID: 29687421
[TBL] [Abstract][Full Text] [Related]
19. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials.
Harigai M; Takeuchi T; Smolen JS; Winthrop KL; Nishikawa A; Rooney TP; Saifan CG; Issa M; Isaka Y; Akashi N; Ishii T; Tanaka Y
Mod Rheumatol; 2020 Jan; 30(1):36-43. PubMed ID: 30784354
[No Abstract] [Full Text] [Related]
20. Janus Kinase Inhibition in the Aicardi-Goutières Syndrome.
Vanderver A; Adang L; Gavazzi F; McDonald K; Helman G; Frank DB; Jaffe N; Yum SW; Collins A; Keller SR; Lebon P; Meritet JF; Rhee J; Takanohashi A; Armangue T; Ulrick N; Sherbini O; Koh J; Peer K; Besnier C; Scher C; Boyle K; Dubbs H; Kramer-Golinkoff J; Pizzino A; Woidill S; Shults J
N Engl J Med; 2020 Sep; 383(10):986-989. PubMed ID: 32877590
[No Abstract] [Full Text] [Related]
[Next] [New Search]
